ArticleBMC public health2026
Impact of COVID-19 on tuberculosis mortality in Japan: a retrospective analysis of national surveillance data from 2017 to 2022.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe coronavirus disease 2019 (COVID‑19) pandemic has disrupted tuberculosis (TB) services globally, but its impact on TB mortality in Japan-where the TB burden is concentrated among older adults-remains unclear. This study assessed trends in TB mortality before and during the COVID‑19 pandemic and examined whether being diagnosed during the pandemic was associated with TB mortality.
methodsWe analyzed anonymized, individual‑level cohort data for all patients notified with active TB to the national surveillance system between 1 January 2017 and 31 December 2022. TB‑specific mortality within 365 days of notification was evaluated across three periods: pre‑COVID‑19, pre‑Omicron, and Omicron. Mortality rates per 100 person‑years were calculated, and Cox proportional hazards models, allowing for a time‑varying effect of age, were used to estimate adjusted hazard ratios (aHRs) for TB death in the overall cohort and in age‑stratified analyses. Covariates included demographic, clinical, and health‑system factors recorded at baseline.
resultsTB mortality increased from 10.1 (95% confidence interval [CI] 9.7-10.4) to 12.7 per 100 person-years (95% CI 12.0-13.5) between the pre-COVID-19 and Omicron periods. This increase was driven primarily by adults aged ≥ 65 years, whose mortality rose from 15.2 (95% CI 14.7-15.8) to 18.5 per 100 person‑years (95% CI 17.4-19.7). In the adjusted models, being diagnosed during the Omicron period was associated with higher TB mortality among adults aged ≥ 65 years (aHR 1.10, 95% CI 1.03-1.18). Among those aged 0-64 years, estimates were imprecise due to the small number of TB deaths (aHR 1.09, 95% CI 0.78-1.53), but the point estimates were similar across age groups. Thus, the difference in statistical significance should not be interpreted as evidence of a true subgroup difference.
conclusionsTB mortality in Japan increased during the COVID‑19 pandemic, particularly during the Omicron period, with the greatest impact observed among older adults. Although statistical significance varied by age group, similar point estimates suggest a broadly consistent effect across ages. These findings highlight the need to strengthen TB care pathways for older adults and ensure continuity of TB services during future public health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.